Pharmafile Logo
Pharmafocus logo
Advanced Search

Revolade

Showing 8 posts of 8 posts found.

Novartis’ Promacta cleared by FDA for first-line use in severe aplastic anaemia

November 19, 2018
Sales and Marketing FDA, Novartis, Promacta, Revolade, US, aplastic anaemia, pharma

Novartis has secured expanded approval from the FDA for Promacta (eltrombopag), allowing it to now be used in combination with …

News

Novartis presents strong results in rare blood disorder trials

June 10, 2016
Medical Communications, Research and Development Jakavi, Novartis, Revolade, blood disorder

Novartis has released data from two late-stage trials for rare blood disorders, which showed that Javi (ruxolitinib) is superior to …

News

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016
Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …

News
GSK sign

GSK submits new Promacta licence

March 3, 2014
Sales and Marketing GSK, NICE, Promacta, Revolade, blood, eltrombopag

GlaxoSmithKline is seeking a new licence for its blood disorder drug Promacta in patients with severe aplastic anaemia. Specifically, the …

News
Revolade image

GSK’s Promacta extends US licence

November 22, 2012
Sales and Marketing FDA, GSK, Promacta, Revolade

GlaxoSmithKline’s Promacta has received a new indication from the FDA which means it can be used for patients with thrombocytopenia …

News
Revolade image

GSK guilty of off-label promotion

November 9, 2012
Medical Communications, Sales and Marketing GSK, PMCPA, Revolade

GlaxoSmithKline has been found to have breached three clauses in the ABPI Code of Practice following a complaint from a …

News

NICE rejects GSK’s Revolade

June 10, 2010
Sales and Marketing ITP, NICE, Revolade

NICE has rejected GlaxoSmithKline’s Revolade saying in draft guidance that the blood disorder drug’s benefits were unclear. The watchdog assessed …

News

Revolade gets European go ahead

March 15, 2010
Sales and Marketing GlaxoSmithKline, Revolade, thrombocytopenia

European regulators have approved GlaxoSmithKline’s Revolade to treat reduced platelet count in patients with a rare blood disorder. Revolade (eltrombopag) …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026